Hepatitis B Virus Status and Clinical Outcomes in IgA Nephropathy

Mei-zhu Gao,Lin-lin Xu,Yang Li,Xin Wang,Pei Chen,Su-fang Shi,Li-jun Liu,Ji-cheng Lv,Fu-Yuan Hong,Hong Zhang,Xu-jie Zhou
DOI: https://doi.org/10.1016/j.ekir.2024.01.009
IF: 6.234
2024-01-12
Kidney International Reports
Abstract:Introduction IgA nephropathy (IgAN) has been reported to coexist with hepatitis B virus (HBV) infection. Despite the clinical significance of this association, there is a lack of comprehensive research investigating the impact of various common conditions following HBV infection and the potential influence of anti-HBV therapy on the progression of IgAN. Methods We investigated three distinct states of HBV infection, including chronic HBV infection, resolved HBV infection, and the deposition of hepatitis B antigens in renal tissue, in a follow-up database of 1961 IgAN patients. IgAN progression was defined as a loss of estimated glomerular filtration rate >40%. Multivariable cause-specific hazards models to analyze the relationship between HBV states and IgAN progression. Results Chronic HBV infection was identified as an independent risk factor for IgAN progression, supported by both pre-matching analysis (HR, 1.61; 95% CI 1.06-2.44; P=0.024) and propensity-score matching analysis (HR, 1.74; 95% CI 1.28-2.37; P 0.05). Conclusion Chronic HBV infection is an independent risk factor for IgAN progression, while resolved HBV infection is not. In patients with IgAN, management of concurrent chronic HBV infection should be enhanced. The presence of HBV deposition in the kidneys and the use of anti-HBV medications do not impact the kidney disease progression in IgAN patients with concurrent HBV infection.
urology & nephrology
What problem does this paper attempt to address?